Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Böck, Stefan [VerfasserIn]   i
 Vehling-Kaiser, Ursula [VerfasserIn]   i
 Waldschmidt, Dirk [VerfasserIn]   i
 Kettner, Erika [VerfasserIn]   i
 Märten, Angela [VerfasserIn]   i
 Winkelmann, Cornelia [VerfasserIn]   i
 Klein, Stefan [VerfasserIn]   i
 Kojouharoff, Georgi [VerfasserIn]   i
 Gauler, Thomas [VerfasserIn]   i
 Fischer von Weikersthal, Ludwig [VerfasserIn]   i
 Clemens, Michael R. [VerfasserIn]   i
 Geißler, Michael [VerfasserIn]   i
 Greten, Tim F. [VerfasserIn]   i
 Hegewisch-Becker, Susanna [VerfasserIn]   i
 Neugebauer, Sascha [VerfasserIn]   i
 Heinemann, Volker [VerfasserIn]   i
Titel:Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer
Titelzusatz:an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie"
Verf.angabe:Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, Erika Kettner, Angela Märten, Cornelia Winkelmann, Stefan Klein, Georgi Kojouharoff, Thomas Gauler, Ludwig Fischer von Weikersthal, Michael R. Clemens, Michael Geissler, Tim F. Greten, Susanna Hegewisch-Becker, Sascha Neugebauer and Volker Heinemann
Jahr:2010
Umfang:7 S.
Fussnoten:Gesehen am 26.01.2023
Titel Quelle:Enthalten in: Anti-cancer drugs
Ort Quelle:Hagerstown, Md. : Lippincott Williams & Wilkins, 1990
Jahr Quelle:2010
Band/Heft Quelle:21(2010), 1, Seite 94-100
ISSN Quelle:1473-5741
Abstract:To date, only limited toxicity data are available for the combination of erlotinib with either capecitabine or gemcitabine as front-line therapy for advanced pancreatic cancer. Within a randomized phase III trial, 281 treatment-naive patients were randomly assigned between capecitabine (2000 mg/m2/day, for 14 days, once every 3 weeks) plus erlotinib (150 mg/day, arm A) and gemcitabine (1000 mg/m2 as a 30-min infusion) plus erlotinib (150 mg/day, arm B). In case of treatment failure, patients were crossed over to a second-line treatment with the comparator cytostatic drug without erlotinib. The primary study endpoint was the time to treatment failure of second-line therapy (TTF2). This interim analysis of toxicity contains safety data from the first 127 randomized patients. During first-line therapy, patients received a median number of three treatment cycles (range 0-13) in both the arms. Regarding chemotherapy, a treatment delay was observed in 12% of the cycles in arm A and in 22% of the cycles in arm B. Dose reductions of the cytostatic drug were performed in 18 and 27% of treatment cycles, respectively. Erlotinib dose reductions were performed in 6 and 11% of all cycles. Grade 3/4 hematological toxicity was <10% in both the arms; major grade 3/4 toxicities in arms A and B were diarrhea (9 vs. 7%), skin rash (4 vs. 12%), and hand-foot syndrome (7 vs. 0%). No treatment-related death was observed. In conclusion, this interim safety analysis suggests that treatment with erlotinib 150 mg/day is feasible in combination with capecitabine or gemcitabine.
DOI:doi:10.1097/CAD.0b013e32833123ed
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1097/CAD.0b013e32833123ed
 Volltext: https://journals.lww.com/anti-cancerdrugs/Fulltext/2010/01000/Erlotinib_150_mg_daily_plus_chemotherapy_in.10.aspx
 DOI: https://doi.org/10.1097/CAD.0b013e32833123ed
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1832495221
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69010582   QR-Code
zum Seitenanfang